Lord's Mark Industries Limited, an Indian medical technology company, has secured registration with the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for its haemodialysis system. This marks a significant milestone for the company's AI-powered dialysis ecosystem, which is designed to provide integrated renal care. The registration covers Renalyx Health Systems Pvt. Ltd. as a manufacturer, with its haemodialysis system for institutional and home use registered under GMDN Code 58131.
The company's AI-powered dialysis ecosystem is a connected, intelligence-led renal-care platform that combines AI clinical intelligence, operational delivery, and remote patient monitoring. At its core is the Renalyx machine, supported by RenalOS, the company's AI-powered clinical intelligence platform, and an integrated operational model designed to extend care beyond the dialysis session. This technology enables real-time monitoring of treatment parameters, generates predictive alerts, and provides data-driven decision support during dialysis sessions.
Lord's Mark Industries Limited plans to start exporting its machine to the UK and UK-allied countries from early January 2027. The company positions this milestone as India's first and the world's first such AI-powered dialysis ecosystem to secure the regulatory milestone at this pace. This achievement is also seen as a significant step towards taking Indian medical technology to global markets.
The company's proposed international business model extends beyond the sale of dialysis machines. Lord's Mark plans to explore a dual pathway - supplying its Renalyx systems to healthcare providers while also establishing and operating its own dialysis centres. This creates the potential for the company to participate across the renal-care value chain - from medical technology and AI-driven clinical intelligence to infrastructure, centre operations, and patient care delivery.
Dr. Sachidanand Upadhyay, Managing Director and CEO of Lord's Mark Industries Limited, said that this milestone validates the company's vision of building Indian medical technology that can compete and create impact in global markets. The MHRA registration gives the company an important platform to explore the UK and UK-allied markets, where it sees significant potential for both technology deployment and its own dialysis-centre operations.
The international push represents another chapter in Lord's Mark Industries' broader healthcare strategy: building advanced medical technologies in India that can compete and create impact in global markets. The Renalyx platform has been positioned by the company as an indigenous smart haemodialysis system developed in India, with the broader ecosystem integrating the machine with AI-powered clinical intelligence and managed dialysis operations.
The MHRA communication confirms that Renalyx Health Systems Pvt. Ltd. is registered as a manufacturer and that its haemodialysis system for institutional/home use is registered. Lord's Mark's UK expansion is being positioned as a globalisation journey for an Indian-built healthcare technology platform - taking the company from an indigenous dialysis innovation to an international renal-care business.
Key points
- Lord's Mark Industries Limited secures MHRA registration for its AI-powered dialysis ecosystem.
- The company plans to start exporting its machine to the UK and UK-allied countries from early January 2027.
- The registration marks a significant milestone for India's medical technology sector, demonstrating the country's ability to develop and export advanced medical technologies.
